In
this work, three new pharmaceutical salts of fenbendazole (FNB),
a benzimidazole-based anthelmintic drug, with sulfonic acids have
been obtained and thoroughly investigated by different analytical
techniques, including thermal methods, infrared/Raman spectroscopy,
and theoretical methods (periodic DFT computations and Bader analyses
of the crystalline electronic density). Single-crystal and high-resolution
synchrotron powder X-ray diffraction data for the first time made
it possible to determine the crystal structures of mesylate and tosylate
salts of the drug, which were further validated by dispersion-corrected
density functional theory calculations. All the solid forms were stabilized
by a robust R2
2(8) supramolecular motif formed by relatively strong N–H···O
hydrogen bonds. In the monohydrate of FNB tosylate, a considerable
gain in the stabilization energy was due to the intermolecular interactions
generated by the water molecules. A careful examination of the solubility–pH
profile of the FNB salts revealed that, despite being thermodynamically
unstable within the physiologically relevant pH range, the new solid
forms demonstrated superior dissolution performance in terms of both
the apparent solubility and the release rate in comparison to the
parent drug. Since FNB has also been reported to possess anticancer
activity, improving the drug’s poor physicochemical properties
through salt formation with the selected sulfonic acids is expected
to promote further investigations toward repurposing of this potent
compound.